Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $49 price target.
April 12, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences and maintained a $49 price target.
The reiteration of an Overweight rating and maintenance of a $49 price target by a reputable analyst suggests a positive outlook for Harmony Biosciences, likely leading to increased investor confidence and potential upward movement in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100